Warberg Asset Management’s Rein Therapeutics RNTX Stock Holding History
Bought
Maintained
Sold
Other funds holding RNTX
Warberg Asset Management's RNTX Position: Q3 2026 in Review
Warberg Asset Management reduced its Rein Therapeutics (RNTX) stake by 3% in Q3 2026, selling an estimated $2.46K and leaving 96,000 shares worth $78K. The position accounts for 0.01% of the portfolio, ranked #156.
Warberg Asset Management first reported a position in RNTX in Q2 2024 and has held it in 5 quarters since. The position peaked at $101K in Q2 2026. 63 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.
- Warberg Asset Management held 96,000 shares of Rein Therapeutics worth $78K as of Q3 2026.
- Warberg Asset Management sold 3,000 Rein Therapeutics shares in Q3 2026, an estimated $2.46K.
- Rein Therapeutics made up 0.01% of Warberg Asset Management's portfolio in Q3 2026, its #156 holding.
- Warberg Asset Management first reported a position in Rein Therapeutics in Q2 2024 and has held it in 5 quarters since.
- Warberg Asset Management's Rein Therapeutics position peaked at $101K in Q2 2026.
- 63 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.
Based on Warberg Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.